Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

Boehringer Ingelheim and 3T announce second cancer immunotherapy partnership

The collaboration brings the potential milestone payments of the agreements to $538.5m

- PMLiVE

Boehringer Ingelheim and Ribo announce liver disease partnership worth over $2bn

More than 440 million people worldwide are estimated to live with the inflammatory liver disease NASH

- PMLiVE

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

- PMLiVE

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

The acquisition marks a significant boost to Boehringer’s immuno-oncology portfolio

- PMLiVE

Boehringer Ingelheim reveals new corporate branding

The evolved brand includes the company’s first-ever brand claim, Life Forward

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

- PMLiVE

Boehringer sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for selected medicines

- PMLiVE

Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease

Approximately 47 million people in the EU are affected by the long-term kidney condition

- PMLiVE

Novartis acquires DTx Pharma in deal worth up to $1bn

The agreement gives Novartis access to three preclinical neuroscience programmes

- PMLiVE

Boehringer’s spesolimab shows promise in generalised pustular psoriasis prevention

The therapy prevented flares in patients with the chronic skin disease for over 48 weeks

- PMLiVE

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

The deal to develop a small-molecule inhibitor could be worth over $480m

- PMLiVE

Eli Lilly/Boehringer’s Jardiance for children with type 2 diabetes accepted by FDA

The incidence of type 2 diabetes in children has nearly doubled over the past two decades

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links